The pro-arrhythmic risk of K+ATP-channel openers in ischemic heart disease may be overestimated as it typically requires high doses, though further clinical studies are needed before widespread application.
No takes yet. Share an insight, caveat, or question.
K+ATP openers may carry lower pro-arrhythmic risk at standard doses; leaves open net clinical effects in ischemic heart disease pending trials.
Arthur A M Wilde (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: